Literature DB >> 21997438

[Blood, blood components and plasma derivatives. Guideline-based implementation].

M U Heim1.   

Abstract

The transfusion act authorized the German Medical Association to provide "guidelines for therapy with blood components and plasma derivatives" by a working party for the critical use of blood products to help to protect patients from avoidable risks. Responsible and carefully considered use of blood products is mandatory, particularly because obtaining them requires the willingness of numerous volunteers to donate blood. The individual recommendations were evaluated by evidence-based criteria and for many medical interventions so that they will serve to provide comprehensive operational procedures for transfusion personnel in clinics.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21997438     DOI: 10.1007/s00063-011-0016-7

Source DB:  PubMed          Journal:  Med Klin Intensivmed Notfmed        ISSN: 2193-6218            Impact factor:   0.840


  2 in total

1.  Prevention and treatment of coagulopathy in patients receiving massive transfusions.

Authors:  M Levi; D Fries; H Gombotz; Ph van der Linden; B Nascimento; J L Callum; S Bélisle; S Rizoli; J-F Hardy; P I Johansson; C M Samama; O Grottke; R Rossaint; C P Henny; J C Goslings; O M Theusinger; D R Spahn; M T Ganter; J R Hess; R P Dutton; T M Scalea; J H Levy; P C Spinella; S Panzer; H W Reesink
Journal:  Vox Sang       Date:  2011-08       Impact factor: 2.144

2.  Dose of prophylactic platelet transfusions and prevention of hemorrhage.

Authors:  Sherrill J Slichter; Richard M Kaufman; Susan F Assmann; Jeffrey McCullough; Darrell J Triulzi; Ronald G Strauss; Terry B Gernsheimer; Paul M Ness; Mark E Brecher; Cassandra D Josephson; Barbara A Konkle; Robert D Woodson; Thomas L Ortel; Christopher D Hillyer; Donna L Skerrett; Keith R McCrae; Steven R Sloan; Lynne Uhl; James N George; Victor M Aquino; Catherine S Manno; Janice G McFarland; John R Hess; Cindy Leissinger; Suzanne Granger
Journal:  N Engl J Med       Date:  2010-02-18       Impact factor: 91.245

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.